Sanofi (SNY), 2024 Q4 earnings digest

from Earnings Report Digest · host ValueVerge

$SNY has released its earnings report, highlighting a strong performance for Q4 2024 with net sales up by 10.3% to €10.6 billion, continuing a trend of double-digit growth. Major products like Dupixent and Beyfortus are serving as growth drivers, while the gross margin is slightly down to 74.3%. Future risks include potential price competition and regulatory uncertainties.

Episode metadata supplied by the publisher feed · Published Jan 31, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Sanofi (SNY), 2024 Q4 earnings digest

0:00 1:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Earnings Report Digest?

This episode is 1 minute long.

When was this Earnings Report Digest episode published?

This episode was published on January 31, 2025.

Can I download this Earnings Report Digest episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!